DIL Dyadic International

Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that Mark Emalfarb, Dyadic's President and Chief Executive Officer, will make a presentation at the Prudential Equity Group, LLC "Inside Our Best Ideas" Conference to be held at the Grand Summit Resort Hotel in Mount Snow, Vermont, on September 27-29, 2006. Mr. Emalfarb's presentation is scheduled for September 27 at 9:30 a.m. EDT. A simultaneous webcast of the presentation may be accessed by clicking the webcast link at http://www.dyadic.com. A replay will be available for 30 days at the same internet address. "The 60-minute format for this presentation will give me time to provide an in-depth analysis of Dyadic's technologies, current activities, and strategy for the future," Mr. Emalfarb said. Mr. Emalfarb plans to discuss Dyadic's progress in the development of its proprietary enabling platform technologies, which are broadly applicable for the discovery, development and large-scale production of new, improved and/or more affordable products in three core business areas: -- Biorefineries, including the Company's recent advances in the development of its patented and proprietary enzyme mixtures to make abundant low-cost sugars from agricultural plant materials. Sugars can be used in place of petroleum to produce ethanol, plastics and polymers in a variety of manufacturing and refining processes. -- Biosciences, updating Dyadic's efforts to leverage its patented C1 Host Technology to facilitate more efficient discovery, development and production of new, improved and/or more affordable human antibodies, as well as other protein drugs; and, -- Enzymes, detailing the Company's progress in expanding its Enzyme Business beyond textiles to larger and more profitable markets including pulp and paper and animal feed. About Dyadic Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States of America, Hong Kong and mainland China, Poland and The Netherlands, is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.